WallStSmart

Alpha Tau Medical Ltd (DRTS)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).

DRTS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -1.47

VRTX

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DRTS.

VRTXUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$952.53

Current Price

$446.83

$505.70 discount

UndervaluedFair: $952.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DRTS1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.89B9/10

Large-cap with strong market position

Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

DRTS4 concerns · Avg: 3.8/10
Price/BookValuation
12.1x4/10

Trading at 12.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$844.55M3/10

Smaller company, higher risk/reward

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DRTS

The strongest argument for DRTS centers on Debt/Equity.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : DRTS

The primary concerns for DRTS are Price/Book, Revenue Growth, EPS Growth.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

DRTS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

DRTS carries more volatility with a beta of 1.20 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (68/100 vs 17/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alpha Tau Medical Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?